Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

65.63 +1.37 (+2.13%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc ADR

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
59 60 Next >
Comparative Study: AstraZeneca And Industry Competitors In Pharmaceuticals Industry
Via Benzinga
Can Diabetes, Weight-Loss Drugs Get Even Better?
Via Investor Brand Network
Can Diabetes, Weight-Loss Drugs Get Even Better?
EQNX::TICKER_START (NASDAQ:LEXX,NYSE:NVO:NYSE:PFE,NYSE:MRK,NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
Understanding AstraZeneca's Position In Pharmaceuticals Industry Compared To Competitors
Via Benzinga
3 No-Brainer Stocks to Buy for Under $100 Right Now
A couple of these stocks might not be available for under $100 for too much longer. 
Via The Motley Fool
Why Is LumiraDx (LMDX) Stock Down 35% Today?
LumiraDx stock is falling on Tuesday as shares of LMDX stock give up some of the gains they saw on Monday after announcing a partnership. 
Via InvestorPlace
US Food and Drug Administration accepts for review AstraZeneca’s Supplemental Biologics License Application for self-administration of FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal)
From AstraZeneca
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial
From AstraZeneca
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial
From AstraZeneca
Via Business Wire
Datopotamab deruxtecan significantly extended progression-free survival vs. chemotherapy in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
From AstraZeneca
Via Business Wire
Why Is LumiraDx (LMDX) Stock Up 323% Today?
LumiraDx stock is rising higher on Monday with heavy trading of LMDX shares after announcing a partnership with AstraZeneca. 
Via InvestorPlace
Datopotamab deruxtecan plus IMFINZI® (durvalumab) demonstrated robust and durable tumor responses in 1st-line treatment of patients with metastatic triple-negative breast cancer in BEGONIA Phase Ib/II trial
From AstraZeneca
Via Business Wire
IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer
From AstraZeneca
Via Business Wire
TAGRISSO® (osimertinib) plus chemotherapy reduced the risk of disease progression in the brain by 42% in patients with EGFR-mutated advanced lung cancer and brain metastases at baseline
From AstraZeneca
Via Business Wire
Stock Market Struggles As Treasury Yields Soar; Tesla, Nvidia Among Notable Losers: Weekly Review
The major indexes saw significant loses as Treasury yields soared. 
Via Investor's Business Daily
Merck Signs Multi-Billion Deal With Japan's Daiichi Sankyo For Cancer Therapy Drug Development
Merck & Company, Inc. (NYSE: MRK) and Japan's Daiichi Sankyo Co. Ltd. (OTC: DSKYF) entered into a global development and commercialization agreement. 
Via Benzinga
IMFINZI® (durvalumab) plus chemotherapy more than doubled pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers versus chemotherapy alone
From AstraZeneca
Via Business Wire
Why Is AstraZeneca Stock Trading Lower Today?
AstraZeneca Plc (NASDAQ: AZN) shares are trading lower after a data abstract on its experimental drug, datopotamab deruxtecan, for lung cancer patients in a late-stage trial disappointed some... 
Via Benzinga
Why AstraZeneca's Disappointing Lung Cancer Update Also Tripped Gilead Stock
The companies are hoping to use antibody drug conjugates in lung cancer patients. 
Via Investor's Business Daily
Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing
The company can begin a pivotal study of its treatment for cardiomyopathy. 
Via Investor's Business Daily
Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
United Airlines, Interactive Brokers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures traded lower this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
FDA Approves Merck's Top Selling Drug, Keytruda For Expanded Use In Lung Cancer Indication
The FDA approved Merck & Co Inc's (NYSE: MRK) Keytruda for resectable (tumors ≥4 centimeters [cm] or node-positive) non-small cell lung cancer (NSCLC) in combination with platinum-containing... 
Via Benzinga
Exposures Product Safety
Pfizer, Sanofi's Respiratory Syncytial Virus Products Faces Insurance And Logistical Hurdles To Protect Infants
As the respiratory virus season kicks off, healthcare providers are racing against time to offer Pfizer Inc's (NYSE: PFE) vaccine, Abrysvo, to pregnant patients and Sanofi SA's (NASDAQ:  
Via Benzinga
Bitcoin's ETF Approval Rumor, Pfizer Slashes Annual Outlook, Activist Shareholder Shakes Up News Corp's Status Quo: Today's Top Stories
Benzinga Bitcoin Spiked On False ETF Approval Rumor 
Via Benzinga
Topics ETFs
AstraZeneca's Tagrisso-Chemo Combo Under FDA Priority Review For Most Common Form Of Lung Cancer
AstraZeneca Plc's (NASDAQ: AZN) supplemental New Drug Application for Tagrisso (osimertinib) in combination with chemotherapy has been accepted and  
Via Benzinga
Exposures Product Safety
TAGRISSO® Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-Mutated Advanced Lung Cancer
From AstraZeneca
Via Business Wire
Week In Review: Two China Biopharmas Announce Billion Dollar Deals
MediLink Therapeutics out-licensed global rights for its antibody-drug conjugate candidate to BioNTech in a $1.1 billion agreement. Meanwhile, BioMap formed a collaboration with Sanofi in a deal with... 
Via Talk Markets
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
59 60 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.